No Difference in Infection Rates Among SLE Drugs
Rates of serious infection and mortality among patients with systemic lupus erythematosus (SLE) did not depend on the immunosuppressive drug regimen they were on, investigators reported.
News
Ilaris Gets FDA Approval for Rare Febrile Disorders
Ilaris was previously approved for use in systemic JIA and CAPS. The FDA has expanded this to include TRAPS, Hyper-IgD and FMF based on clinical trials.
Anti-Sclerostin Drug Prevents Vertebral Fractures in Post-Menopausal Osteoporosis
Romosozumab is being developed as a novel therapy for osteoporosis. It is a monoclonal antibody that binds sclerostin, and has been shown to increase bone formation while decreasing bone resorption.
FDA Approves New Amgen Biosimilar for Adalimumab
2016 has been a big year for biosimilars in rheumatology.
FDA Approves Stelara for Crohn's Colitis
The anti-IL-12/IL-23 inhibitor, Stelara (ustekinumab) has been FDA approved for the treatment of psoriasis and psoriatic arthritis. In the last week, the EMA's CHMP has recommended that the drug also be approved for use in Crohn's disease.
RheumNow Week in Review – 23 September 2016
Dr. Jack Cush reviews highlights, news and articles from the past week at RheumNow.com:
Restricting High Price Drugs - A Dangerous Trend?
Who makes billions in profits and millions in bonus monies? PBMs and insurers, thats who. This week United Healthcare and Express Scripts announced new plans to restrict patient and prescriber access to popular, expensive, albeit FDA-approved, medications and biologics. Who benefits, who loses?
Recognizing Arboviral Infections in Rheumatic Disease Patients.
What does sex have to do with it? Although the Zika virus infection is known to be sexually transmitted, the same cannot be claimed for Dengue or Chikungunya.
The Immunodeficiency and Autoimmunity Relationship
The world of PID (Primary immunodeficiency diseases) has changed remarkably over the past 5 years.
Wearable Activity Trackers Don't Improve Weight Loss
JAMA has reported the results of a 24-month trial showing that obese individuals on a long-term healthy diet and exercise program do not have significantly more weight loss from using a wearable device that tracks their activity.
After the 1st TNF Inhibitor, a Non-TNF Biologic is Next Best
Most US rheumatologists use multiple TNF inhibitors before switching. A new French study suggests that "other-MOA", non-TNF biologics are more effective after failing a TNF inhibitor.
Demyelinating Disease is a Rare Complication of TNF Inhibition.
A recent review has shown that tumor necrosis factor-α inhibitors (TNFi) rarely cause MS-like disorders.
